Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises CELLINK in connection with the acquisition of Ginolis
Mandate

Vinge advises CELLINK in connection with the acquisition of Ginolis

February 15, 2021 M&A Capital Markets and Public M&A Intellectual Property

Vinge has advised CELLINK AB (publ) in connection with the acquisition of all shares in Ginolis Oy. Ginolis conducts operations in relation to automated diagnostics and provides advanced robotic solutions to the medical- and diagnostics industries.

The purchase price on a cash and debt free basis amount to EUR 70 million. Forty per cent of the purchase price will be paid with newly issued class B shares in CELLINK, with the remainder in cash.

Vinge’s team mainly consisted of Anders Strid, Johanna Hamrefält (project manager M&A), Anna Maria Lagerqvist Gahm and Alexander Lindeberg (IP), Aleksandar Bajic (M&A), Martin Svanberg (W&I) in addition to Edin Agic (Capital Markets). Krogerus Attorneys acted as local counsel in Finland.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025